Efficacy and tolerability of chitin-glucan combined with simethicone (GASTRAP® DIRECT) in irritable bowel syndrome: A prospective, open-label, multicenter study

doi:10.4292/wjgpt.v15.i3.90757

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1264)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-8) series, Tables (1-5) series.

Item

Count

PDF

WORD

HTML

751

Figures (1-8)

Tables (1-5)

Sum=900

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

167

Sum=233

Publishing Process of This Article

Item

Count

Browse

Download

Sum=88

May 28, 2024 (publication date) through Jul 17, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Gastrointest Pharmacol Ther. May 28, 2024; 15(3): 90757
Published online May 28, 2024. doi: 10.4292/wjgpt.v15.i3.90757

Table 2 Change in paired scores of irritable bowel syndrome symptoms after week 4 of GASTRAP^® DIRECT treatment (visit 1 to visit 3)

IBS symptoms	V1, mean ± SEM	V3, mean ± SEM	Responders, ∆ > 30%, n [% (95%CI)]	Paired decrease, mean ± SE (%)
Abdominal pain (0–10)	5.8 ± 2.4	2.9 ± 2.0^c	64/96 [67 (57; 75)]	-2.9 ± 0.3 (50)
Bloating (0–10)	8.0 ± 1.7	4.7 ± 2.9^c	58/96 [60 (50; 70)]	-3.2 ± 0.3 (40)
Abdominal distension (0–10)	7.2 ± 2.1	4.4 ± 3.1^c	51/96 [53 (43; 63)]	-2.8 ± 0.4 (39)
Impact of global symptoms on daily life	7.1 ± 2.0	4.6 ± 2.9^c	51/94 [54 (44; 64)]	-2.5 ± 0.3 (35)

^cP < 0.001.

95%CI: Confidence interval of the responder rate (Wilson method); IBS: Irritable bowel syndrome; V: Visit.

Citation: Talbodec N, Le Roy P, Fournier P, Lesage B, Lepoutre E, Castex F, Godchaux JM, Vandeville L, Bismuth B, Lesage X, Bayart P, Genin M, Rousseaux C, Maquet V, Modica S, Desreumaux P, Valibouze C. Efficacy and tolerability of chitin-glucan combined with simethicone (GASTRAP^® DIRECT) in irritable bowel syndrome: A prospective, open-label, multicenter study. World J Gastrointest Pharmacol Ther 2024; 15(3): 90757
URL: https://www.wjgnet.com/2150-5349/full/v15/i3/90757.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v15.i3.90757